Cantor Fitzgerald Reiterates “Overweight” Rating for Stratasys (NASDAQ:SSYS)

Stratasys (NASDAQ:SSYS)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Monday,Benzinga reports. They presently have a $12.00 price target on the technology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential downside of 3.61% from the company’s current price.

Several other brokerages have also recently weighed in on SSYS. Craig Hallum upped their price objective on shares of Stratasys from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price target on shares of Stratasys in a report on Monday. Finally, StockNews.com raised Stratasys from a “hold” rating to a “buy” rating in a research note on Wednesday, December 25th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

Stratasys Price Performance

Stratasys stock opened at $12.45 on Monday. The business has a 50 day simple moving average of $9.47 and a 200 day simple moving average of $8.37. Stratasys has a one year low of $6.05 and a one year high of $13.98. The company has a market capitalization of $888.68 million, a PE ratio of -9.43 and a beta of 1.31.

Stratasys (NASDAQ:SSYS) last issued its earnings results on Wednesday, November 13th. The technology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.05. Stratasys had a negative net margin of 16.13% and a negative return on equity of 3.75%. The company had revenue of $140.00 million for the quarter, compared to the consensus estimate of $139.49 million. During the same quarter in the previous year, the company earned ($0.05) EPS. The firm’s revenue for the quarter was down 13.6% compared to the same quarter last year. Equities analysts anticipate that Stratasys will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SSYS. Rubric Capital Management LP increased its stake in shares of Stratasys by 3.7% in the 3rd quarter. Rubric Capital Management LP now owns 6,191,000 shares of the technology company’s stock valued at $51,447,000 after buying an additional 222,297 shares during the period. Exchange Traded Concepts LLC increased its position in Stratasys by 0.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 1,399,898 shares of the technology company’s stock worth $12,445,000 after purchasing an additional 9,522 shares during the period. Clearline Capital LP raised its holdings in Stratasys by 23.3% during the 3rd quarter. Clearline Capital LP now owns 1,367,226 shares of the technology company’s stock worth $11,362,000 after purchasing an additional 258,603 shares during the last quarter. Invenomic Capital Management LP acquired a new position in Stratasys during the 3rd quarter valued at about $10,916,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Stratasys by 53.1% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,153,580 shares of the technology company’s stock valued at $10,255,000 after purchasing an additional 400,000 shares during the last quarter. Institutional investors and hedge funds own 75.77% of the company’s stock.

Stratasys Company Profile

Stratasys Ltd. provides connected polymer-based 3D printing solutions. It offers range of 3D printing systems, which includes polyjet printer, Fused Deposition Modeling (FDM) printers, stereolithography printing systems, origin P3 printers, and selective absorption fusion printer for additive manufacturing, and tooling and rapid prototyping for various vertical markets, such as automotive, aerospace, consumer products and healthcare.